Can immune therapy IVIG calm long COVID's autonomic storm?
NCT ID NCT06305793
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This study tests whether intravenous immunoglobulin (IVIG) can reduce symptoms of autonomic dysfunction—such as dizziness, rapid heartbeat, and fatigue—in people with long COVID. Two hundred participants will receive either IVIG or a placebo (saline) for 9 months, plus coordinated non-drug care. The goal is to see if IVIG improves daily function and symptom severity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IVIG (intravenous immunoglobulin)
- What this could lead to
- If IVIG works, it could provide a treatment for autonomic symptoms like dizziness and rapid heart rate in long COVID patients.
- What could go wrong
- This is a Phase 2 trial with 200 participants, so results are preliminary. IVIG can cause side effects like headache, fever, or allergic reactions, and may not prove effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTONOMIC DYSFUNCTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
All sites listed under NCT06305780
Durham, North Carolina, 27710, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Could exercise retrain the heart in long COVID?
- Can brain games and gentle currents lift long COVID brain fog?
- Fixing sleep, fortifying hearts: a new trial tests the link
- Could a High-Fat diet reset energy in long COVID?
- Can brain training zap long COVID brain fog?